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significant. Statistical analyses were performed with the JMP
software package (SAS Institute).
RESULTS AND DISCUSSION
A missense polymorphism, Val227Ala (GTC→GCC), was iden-
tified in the PPARα gene by SSCP analysis followed by
sequence analysis. Of 401 subjects, 362 were homozygous for
the Val227 allele, 37 were heterozygous for the Val227 and
Ala227 alleles, and two were homozygous for the Ala227
allele. The distribution of these genotypes did not deviate from
Hardy-Weinberg equilibrium.
Table 2 shows the mean values for serum lipid levels, fasting
glucose levels, and BMI according to the PPARα genotype for
both men and women and total subjects. Because only two
subjects were homozygous for the Ala227, we classified the
subjects into two groups, carriers of the Ala227 allele and
non-carriers.
Sex, age, and BMI affect serum lipid levels; therefore, we
examined the relationship between the Val227Ala genotype
and lipid levels separately in men and women, and p values
were calculated after adjustments for age and BMI by multiple
linear regression analysis. It is also known that dietary habits,
exercise, smoking, and alcohol intake influence serum lipid
levels, but we could not obtain information regarding such
factors for our subjects.
Among women, the mean serum total cholesterol and trig-
lyceride levels in carriers of the Ala227 allele were significantly
lower than those in non-carriers (p=0.046 and p=0.038,
respectively). The mean LDL-C level in carriers of the Ala227
allele was lower than that in non-carriers; however, the differ-
ence was not significant (p=0.066). In men, a similar trend
was observed, but the difference was not significant. Mean
HDL-C, fasting glucose levels, and BMI did not differ
significantly between the genotype groups in either women or
men. In the total subjects, the mean serum total cholesterol
level in carriers of the Ala227 allele was significantly lower
than that in non-carriers (p=0.033). The lipid profiles of the
carriers with the Ala227 allele appear favourable compared
with those of non-carriers.
The Val227Ala site is located in the region between the DNA
binding and ligand binding domains of the PPARα gene, which
is also thought to contain the dimerisation domain. It is pos-
sible that the substitution of Val to Ala at codon 227 causes a
functional change in PPARα and that the Ala227 isoform has
higher activity than the Val227 isoform. However, we have no
experimental evidence to support this hypothesis. It will be
necessary to examine differences in the transactivation activi-
ties in vitro as a result of this amino acid substitution.
It was reported that phenotypes related to lipid and glucose
metabolism are strongly influenced by sex in PPARα deficient
mice.17 18 It is assumed that oestrogen signalling plays a role in
lipid and glucose homeostasis via regulation of fatty acid uti-
lisation pathways.18 19 In our present study, the findings
suggest that PPARα gene polymorphisms affect serum lipid
levels, especially in women. Menopause has a significant effect
on serum oestrogen and lipid levels in women; however, we
could not obtain information regarding the menopausal status
Table 1 Clinical characteristics and serum lipid and glucose levels of the subjects
Total subjects Men Women
Numbers of subjects 401 207 194
Age (y) 47.7 (9.1) 49.2 (8.9) 46.2 (9.1)
Total cholesterol (mg/dl) 199.2 (34.1) 195.5 (33.1) 203.2 (34.8)
HDL cholesterol (mg/dl) 53.8 (16.1) 46.5 (13.2) 61.5 (15.3)
Triglycerides (mg/dl) 105.4 (62.1) 121.7 (63.7) 88.1 (55.5)
LDL cholesterol (mg/dl) 124.4 (32.0) 124.7 (31.9) 124.0 (32.2)
Fasting glucose (mg/dl) 92.2 (7.7) 92.6 (7.7) 91.7 (7.7)
BMI (kg/m2) 22.6 (3.0) 22.8 (2.5) 22.3 (3.4)
Values shown are mean (SD).
BMI=body mass index.
Table 2 Effects of the Val227Ala polymorphism of the PPARá gene on the serum lipid and glucose levels and BMI
Genotype
Total
subjects p Men p Women p
Women
(<45 y) p
Total cholesterol (mg/dl) VV 200.7 (34.2) [362] 0.033 196.7 (33.5) [191] 0.30 205.2 (34.5) [171] 0.046 190.7 (29.0) [83] 0.023
AA+AV 185.3 (30.6) [39] 181.6 (25.0) [16] 188.0 (34.3) [23] 170.1 (22.3) [12]
HDL cholesterol (mg/dl) VV 53.6 (16.2) [362] 0.58 46.7 (13.2) [191] 0.17 61.2 (15.8) [171] 0.66 64.1 (15.6) [83] 0.96
AA+AV 55.6 (15.5) [39] 43.5 (12.4) [16] 64.0 (11.3) [23] 65.4 (9.3) [12]
Triglycerides (mg/dl)* VV 107.6 (62.9) [362] 0.26 122.3 (63.9) [191] 0.54 91.1 (57.6) [171] 0.038 79.3 (60.8) [83] 0.055
AA+AV 85.8 (50.7) [39] 114.0 (62.5) [16] 66.2 (28.2) [23] 52.8 (16.1) [12]
LDL cholesterol (mg/dl) VV 125.6 (31.8) [362] 0.10 125.5 (32.0) [191] 0.55 125.8 (31.7) [171] 0.066 110.8 (26.9) [83] 0.054
AA+AV 112.6 (31.2) [39] 115.2 (29.2) [16] 110.7 (33.0) [23] 94.2 (18.7) [12]
Fasting glucose (mg/dl) VV 92.4 (7.4) [362] 0.083 92.8 (7.5) [191] 0.27 92.0 (7.3) [171] 0.15 91.4 (7.6) [83] 0.031
AA+AV 89.7 (9.6) [39] 90.4 (9.0) [16] 89.3 (10.2) [23] 86.1 (7.1) [12]
BMI (kg/m2) VV 22.6 (3.0) [362] 0.18 22.8 (2.5) [191] 0.13 22.4 (3.4) [171] 0.48 21.6 (3.8) [83] 0.30
AA+AV 21.8 (2.6) [39] 21.8 (2.4) [16] 21.8 (2.9) [23] 20.6 (1.6) [12]
Values shown are mean (SD).
p value for lipid levels was calculated by multiple linear regression analyses incorporating age and BMI as covariates.
p value for fasting glucose levels and BMI was calculated by multiple linear regression analysis incorporating age as a covariate.
For multiple linear regression analysis of total subjects, sex was also incorporated as a covariate.
*Statistical tests for triglyceride levels were calculated on log transformed values.
Statistically significant p values are shown in bold.
Numbers of subjects are shown in square brackets. BMI=body mass index.
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of our subjects. For convenience, we selected 95 women under
45 years from our subjects, assuming that most women under
45 years are premenopausal. A stronger association between
the genotypes of the Val227Ala polymorphism and total chol-
esterol levels was observed in women under 45 years than in
the total population of 194 women (p=0.023 v p=0.046)
(table 2). Such data appear to support the above assumption
for a relationship between oestrogen signalling and lipid
homeostasis.
Recently, a Leu162Val polymorphism was identified in
white populations.13 14 20 Vohl et al14 found an association
between the Leu162Val polymorphism and hyperapobetalipo-
proteinaemia in non-diabetic subjects. Flavell et al13 reported
associations between the Leu162Val polymorphism and total
cholesterol, HDL-C, and apolipoprotein AI levels in type II dia-
betic subjects. Furthermore, it was reported that the Val162
isoform increases PPRE dependent transcriptional activity
compared with the Leu162 isoform in in vitro transient trans-
fection assays.13 20 However, we did not find this polymorphism
in our Japanese subjects. In contrast, the Val227Ala polymor-
phism has not been detected in white populations,13 14 20
suggesting that there is variability in the frequencies of PPARα
gene polymorphisms between ethnic groups.
Many association studies of polymorphic markers in candi-
date genes related to lipoprotein metabolism and interper-
sonal variations in serum total and LDL cholesterol levels have
been reported.21–23 However, many of the relationships appear
to differ between populations with the exception of the apoli-
poprotein E polymorphism.21–24 Further epidemiological and
genetic studies are needed to understand the relationship
between the Val227Ala polymorphism in the PPARα gene and
serum lipid levels. It will also be interesting to examine the
relationship between responses to fibrates and the Val227Ala
genotype of the PPARα gene.
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In Finland, mutations in the two major breast cancer suscep-tibility genes BRCA11 and BRCA22 appear to account for aconsiderably lower proportion of hereditary breast cancer
than in other western European countries.3–5 In addition, the
recently identified new susceptibility locus in 13q21 is
expected to explain, at most, one quarter of the hereditary
predisposition to breast cancer.6 Inherited breast cancer
susceptibility may also be the result of mutations in genes
associated with certain rare hereditary syndromes, such as
Li-Fraumeni syndrome7 or ataxia-telangiectasia (AT).8–10
AT is a recessive neurodegenerative disorder resulting from
mutations in the ATM gene.11 It is characterised by progressive
cerebellar ataxia, telangiectasias, sensitivity to ionising radia-
tion, and immunodeficiencies. Furthermore, owing to ATM
involvement in double strand break repair, defects in its
protein function cause genetic instability and, as a conse-
quence, an increased risk of cancer. AT patients are especially
prone to developing lymphatic and leukaemic malignancies,
but also breast cancer. Also AT heterozygotes have an
increased risk of developing breast cancer,8 10 yet a clear
discrepancy remains between the epidemiological data and
the observed low frequency of ATM mutations in breast cancer
patients.12
Recently, Laake et al13 screened 41 AT families from the Nor-
dic countries for ATM mutations. In seven Finnish AT families
included in the study, they observed eight distinct mutations,
some of which were recurrent (partly unpublished results).13
Given the fact that many disease related gene defects are
clearly enriched in the Finnish population owing to founder
effects, genetic drift, and isolation,14 we anticipated that these
“Finnish” ATM mutations might also be found in breast cancer
patients in Finland, possibly contributing to increased breast
cancer susceptibility. Recurrent ATM mutations have been
reported in several countries and within many different ethnic
groups.9 15–19
On these grounds, we decided to screen 162 breast cancer
families and 85 sporadic breast cancer patients for ATM germ-
line mutations previously identified in Finnish AT families. We
were interested to determine the frequency of these mutations
among these different categories of breast cancer patients, as




A total of 215 breast cancer patients from 162 families
originating from central and northern Finland were chosen
for ATM mutation screening. All families, except one in which
two members tested positive for a newly discovered BRCA2
mutation (5797G>T, exon 11) after the ATM study had been
performed, had previously been excluded for BRCA1, BRCA2,
and TP53 mutations.3–5 7 Inclusion criteria for the families with
moderate to high genetic susceptibility to breast cancer were
one or more of the following: (1) at least three (two in combi-
nation with other selection criteria) cases of breast cancer in
first or second degree relatives, (2) early disease onset (<35
years alone, or <45 in combination with other inclusion crite-
ria), (3) bilateral breast cancer, or (4) multiple tumours
including breast cancer in the same person. Additionally, 85
sporadic breast cancer cases from the Oulu area were
included. All patients provided informed consent for obtaining
pedigree data and blood specimens for a study on cancer sus-
ceptibility gene mutations. Reference blood samples from 200
healthy, geographically matched controls were used to validate
the observations from the two test groups. Approval to
perform the study was obtained from the Ethical Board of the
Northern Ostrobotnia Health Care District and the Finnish
Ministry of Social Affairs and Health.
Methods
DNA extraction from blood lymphocyte specimens was
performed using the standard phenol-chloroform method.
The screening of eight distinct ATM germline mutations (table
1) previously detected in Finnish AT families (partly
unpublished results)13 was mainly done by conformation sen-
sitive gel electrophoresis (CSGE).5 Simultaneously, the com-
plete exons and exon-intron boundary regions at the sites of
the known mutations were evaluated for other possible aber-
rations. Samples with a band shift were reamplified and puri-
fied with the QIAquick PCR purification Kit (Qiagen).
Sequencing analysis was performed with the Li-Cor IR2
4200-S DNA Analysis system (Li-Cor Inc, Lincoln, USA) and
using the SequiTherm EXCELTM II DNA Sequencing Kit-LC
(Epicentre Technologies). Oligonucleotides for exons 14, 37,
62, and 65 were as reported by Shayegi et al.20 For exons 4, 5, 48,
49, and 53, the oligonucleotides were designed by using the
Primer3 software. Primer sequences and PCR conditions for
CSGE and sequencing are available upon request.
RESULTS
Identification of pathogenic ATM variants
All detected germline alterations are summarised in tables 2
and 3. Two of the eight ATM mutations previously identified in
Finnish AT families were also detected in the breast cancer
patients studied. 7522G>C (exon 53, Ala2524Pro) was
originally observed in two AT families, FIAT6 and FIAT7, and
was now identified in two women with breast cancer, belong-
ing to separate cancer families (table 2, fig 1, families 003 and
005). The woman in family 003 had breast cancer at the age of
50. Her sister had breast cancer at the age of 59, but owing to
lack of DNA we were unable to determine her carrier status.
However, of her four children, the two sons carried the
7522G>C aberration, both cancer free at ages 49 and 54. Her
two daughters, on the other hand, tested negative for the
mutation, even though they had breast and thyroid cancer at
the ages of 51 and 47, respectively. Interestingly, there were
also multiple cases of cancer on the other side of the family. In
family 005, an identified mutation carrier was diagnosed with
both breast and stomach cancer at 57 and 41, respectively. In
her relatives, other observed cancers included a basal cell car-
cinoma in the proband’s uncle, several cases of stomach can-
cer (in the maternal grandmother, paternal uncle, and
cousin), as well as an unknown cancer in the paternal aunt
and thyroid cancer in a cousin.
In breast cancer family 004 (table 2, fig 1), an alteration in
exon 49 was observed. The insertion of adenine (6903insA)
results in a loss of 685 amino acids from the carboxy terminus
of the ATM protein. The 6903insA mutation had previously
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been detected in two AT families, FIAT4 and FIAT5.
Interestingly, this alteration was now found in three sisters,
who all had breast cancer at ages 40, 47, and 50. Further
investigation of family 004 showed ambiguity in the
genotype-phenotype association (fig 1), as the probands’
cousin who had been diagnosed with breast cancer aged 54
did not carry the mutation. Her sister, however, who was
unaffected at the age of 49, was a carrier. Also, two additional
breast cancer patients (diagnosed at ages 37 and 45) from
another branch of this cancer family tested negative for
6903insA. Interestingly, however, after completion of our ATM
mutation screening, these two cancer cases tested positive for
a newly discovered BRCA2 mutation (5797G>T, exon 11),
which probably explains their hereditary susceptibility to
breast cancer. We then tested all the other available family
members for this particular BRCA2 mutation, but no
additional carriers were found. At present, it appears unlikely
that the BRCA2 mutation positive branch of family 004 would
segregate the 6903insA ATM mutation.
Neither 6903insA nor 7522G>C was seen in the sporadic
breast cancer cases studied or in the healthy controls, indicat-
ing that in addition to being instrumental to AT, these two ATM
mutations could also be related to hereditary predisposition to
breast cancer.
Polymorphic variants
We also found three other germline sequence variants, two in
exon 5 (133C>T and 146C>G) and one in the intronic region
between exons 62 and 63. All these changes were regarded as
polymorphisms (table 3). 133C>T leads to an amino acid sub-
stitution Arg45Trp and was observed in a woman with
bilateral breast cancer at the age of 45. The second exon 5
variant, 146C>G, results in Ser49Cys and was detected in a
woman diagnosed with breast cancer at 60. She had two
sisters, both with breast cancer at ages 48 and 58, but neither
of them carried the alteration. We did not observe any of these
alterations in the sporadic breast cancer group or healthy con-
trols. Furthermore, neither Arg45Trp nor Ser49Cys resides in a
known functional ATM domain, and are thus less likely to
interfere with ATM kinase function. The third sequence
alteration, IVS62+8A>C, was detected in 5/215 (2.3%) of the
familial breast cancer patients, 2/85 (2.4%) of the sporadic
breast cancer cases, and 4/200 (2.0%) of the control samples.
DISCUSSION
We have examined the prevalence of eight different ATM
germline mutations, originally found in Finnish AT families,
in a cohort of 215 breast cancer cases from 162 cancer families,
as well as in 85 sporadic breast cancer patients. Altogether, we
detected five different ATM sequence alterations (tables 2 and
3), two of which (7522G>C and 6903insA) potentially relate
to breast cancer susceptibility. The 7522G>C mutation was
previously found in two AT families also displaying signs of
genetic predisposition to breast cancer (see below). The
6903insA mutation present in two known AT families (see
below) may also be associated with susceptibility to cancer, as
this mutation leads to a truncated ATM protein with loss of
685 amino acids, including the region containing the PI-3
kinase motif.21 The remaining three variants (133C>T,
146C>G, and IVS62+8A>C) were classified as polymor-
phisms. This assumption was based both on their location
Table 1 ATM germline mutations observed in Finnish AT families (partly unpublished results)13
Exon Codon nt change Predicted change in protein Family ID
4–5 Unknown Unknown 200 bp deletion FIAT8
14 602-603 IVS14+3-4delAT Skipping of exon 14 FIAT4
37 1773-1774 IVS37+9A>G Insertion of Val, Ser, and Stop FIAT3, FIAT5
48 2260 6779-6780delTA Truncated protein FIAT7
49* 2303 6903insA Truncated protein FIAT4, FIAT5
53* 2524 7522G>C Ala>Pro FIAT6, FIAT7
62 2904-2905 8710-8715delGAGACA Deletion of Glu and Thr FIAT3
65 3947 9139C>T Arg>Stop FIAT2
*Unpublished mutations.
Table 2 Pathogenic ATM germline changes in families with breast cancer, sporadic breast cancer, and controls
Family ID Phenotype* Exon nt change
Sporadic breast
cancer Controls
003 Br(50)†, Br(59), Br(51), Th(47), Pro(59), Br (71), Sto, Pul (55), Csu 53 7522G>C 0/85 0/200
005 Br(57)+Sto(41)†, Bs(70), Sto, Sto, Sto(41), Csu, Th(55) 53 7522G>C 0/85 0/200
004 Br(50)†, Br(47)+Sar(18)†, Br(40)†, Sto, Bt, Pan(40), Br(54), Sto, Pan, Br(45)‡,
Br(37)‡, Bt, Sto, Sto, Br(30), Bt, Pro, Sto
49 6903insA 0/85 0/200
Br, breast; Bs, basal cell; Bt, brain; Csu, cancer site unknown; Pan, pancreas; Pro, prostate; Pul, pulmonary; Sar, sarcoma; Sto, stomach; Th, thyroid.
*The mutation status has not been defined for all subjects.
†Initially studied probands.
‡Patients subsequently tested positive for BRCA2 mutation 5797G>T.
Table 3 Polymorphisms detected in the ATM gene
nt change aa change
Frequency in the breast cancer patients studied
ControlsWith family history Without family history
133C>T Arg45Trp 1/215 (0.5%) 0/85 0/200
146C>G Ser49Cys 1/215 (0.5%) 0/85 0/200
IVS62+8A>C None 5/215 (2.3%) 2/85 (2.4%) 4/200 (2%)
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away from essential functional domains, and for 146C>G also
on previous studies by Vorechovsky et al22 and Izatt et al,23 who
did not observe loss of heterozygosity (LOH) of the relevant
chromosome region in tumours carrying this alteration. Both
groups also identified 146C>G among healthy controls.
Both of the two Finnish AT families (FIAT6 and FIAT7)
showing 7522G>C originated from northern Finland. In fam-
ily FIAT7, the AT patient carried two different mutant ATM
alleles, 7522G>C and a 2 bp deletion in exon 48. The patient’s
mother, who carried the 7522G>C mutation, had been
diagnosed with childhood leukaemia at the age of 4, followed
by bilateral breast cancer at the age of 37. Tumour cells from
her left breast showed LOH of the wild type allele, as
determined by using the intragenic ATM marker D11S2179
(data not shown). Also, the AT patient’s grandmother had died
from breast cancer at the age of 52. In family FIAT6, the AT
patient was a missense 7522G>C homozygote. It is known
that at least the proband’s maternal grandmother (aged 61)
and also one of her sisters had breast cancer. So far, only a few
missense homozygotes have been identified9 13 and it has been
suggested that these patients would express a milder AT phe-
notype. However, no clear differences were observed in the
phenotypes of these two AT patients from families FIAT6 and
FIAT7. The appearance of 7522G>C in two AT families from
northern Finland suggested that this mutation could also be
more frequent in breast cancer patients originating from the
larger Oulu region. Indeed, the mutation was found in two
families with breast cancer (table 2, families 003 and 005).
Besides 7522G>C, ATM 6903insA was the other putative
breast cancer related alteration seen in this study. The
geographical origin of the 6903insA allele, first identified from
AT families FIAT4 and FIAT5, appeared to be a rural area
slightly west of the city of Tampere. Both AT families showed
excessive cases of breast cancer in the branches segregating
the 6903insA allele, and at relatively young ages (FIAT4, the
proband’s paternal grandmother (aged 53); FIAT5, the
proband’s mother (aged 50) and maternal grandmother’s sis-
ter (aged 51)). Interestingly, the branch of breast cancer fam-
ily 004 displaying the 6903insA mutation also came from west
of Tampere. Neither 7522G>C nor 6903insA was detected
among 200 controls originating from the same geographical
region, suggesting that these two mutations could have some
effects on the carrier phenotype, even when heterozygous.
In families 003 and 004, where we were able to study addi-
tional family members, some discrepancies regarding cancer
phenotype and carrier status were seen (fig 1). Even though
this observation raises questions about the contribution of
these mutations to breast cancer susceptibility, incomplete
penetrance and occurrence of sporadic cancer cases must also
be taken into account. Furthermore, the dominant inheritance
model of cancer predisposition cannot automatically be
assumed to apply to these mutations.
The large size of the ATM gene sets certain limitations to
mutation screening. Most studies have used the protein trun-
cation test, which only detects alterations resulting in a
premature stop codon and therefore a shortened protein
Figure 1 Families with breast cancer exhibiting (A) 7522G>C and (B) 6903insA ATM germline mutations. Filled/open symbols indicate
cancer/non-cancer status. Age at diagnosis, when known, is shown in brackets after the cancer type (Br, breast; Bs, basal cell; Bt, brain; Csu,
cancer site unknown; Pan, pancreas; Pro, prostate; Pul, pulmonary; Sar, sarcoma; Sto, stomach; Th, thyroid). Subjects tested for a specific
mutation are marked + if positive and − if negative. In addition, in a subsequent BRCA2 study of a previously unscreened branch of family
004, two subjects marked with an asterisk tested positive for the 5797G>T mutation. Therefore, other available members of this family were
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product. Missense mutations, however, contributing to the
other of the two putative phenotypically distinct populations
of AT carriers, are not detected with this method.24 25 Also, if
DNA is the only starting template available, as was the case in
this study, it is quite impossible to cost effectively screen large
sample sets for missense mutations. Therefore, and also
because of the anticipation of seeing breast cancer related
geographically recurrent mutations, we concentrated on
studying only the ATM germline mutations previously
recognised from all known Finnish AT patients (partly
unpublished data)13 and used CSGE as the primary screening
method because of its simplicity and high accuracy followed
by DNA sequencing, if required.
ATM is one of the central components of the DNA damage
response, and it interacts with several key proteins such as
p53, Mdm2, BRCA1, Chk2, Nbs1, and Rad17.26 27 Viewed
against this background and considering the existing epide-
miological evidence,10 the fact remains that ATM is a strong
candidate contributing to cancer susceptibility. The low
frequency of mutations within the protein encoding region in
the breast cancer material analysed, however, raises the ques-
tion of whether epigenetic mechanisms (for example,
promoter region hypermethylation) could play an additional
role in ATM silencing. These studies are currently under way in
our laboratory.
We have analysed both familial and sporadic breast cancer
patients for eight ATM germline mutations previously identi-
fied from Finnish AT families (partly unpublished results)13
and found a pathogenic mutation present in 3/162 (1.9%) of
them displaying various indications of hereditary breast can-
cer. These mutations were not observed among sporadic breast
cancer patients or healthy controls. Both of the detected
mutations were also found in AT families originating from the
same geographical region as the breast cancer families
displaying the corresponding mutation, implying the possi-
bility of a founder effect concerning the distribution of
7522G>C and 6903insA. However, to follow this preliminary
lead, a more extensive screening for ATM mutations among
breast cancer families is indicated. In addition, it would be
interesting to investigate whether similar trends are seen with
mutations in other AT families from different parts of the
country.
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Fragile X syndrome is characterised by mild to severe men-tal retardation, minor physical anomalies such as largeears, long facies with a high forehead, joint hyperextensi-
bility, and macro-orchidism, behaviour such as hyperactivity
and social avoidance, and speech and developmental delays.1
Trinucleotide repeat (CGG) expansion mutations account for
nearly all cases of fragile X syndrome with only a few patients
reported with deletions or point mutations in the FMR1
gene.2–4 Expansion beyond approximately 200 repeats (normal
range 5-54 repeats), commonly referred to as a “full
mutation”, usually results in hypermethylation of the FMR1
promoter region with a concomitant loss of FMR1 transcrip-
tion and the protein product of the gene, FMRP.5 People with
55-200 repeats have a premutation, which is unstable and
prone to expansion when transmitted by females to their off-
spring. Premutation carriers produce FMRP and typically have
few manifestations of the syndrome.
It is the loss or severe reduction in FMRP that results in the
fragile X syndrome.6–8 However, there are numerous reports of
subjects with mild phenotypes related to modest FMRP
production.9 Such subjects may have learning disabilities but
are not retarded (IQ>70), and the milder phenotype appears
related to FMRP production arising from transcription of
unmethylated alleles. Typically, such patients are cellular mosa-
ics having both full mutations and premutations (termed “full
mutation/premutation mosaics”), or having full mutations with
varying degrees of methylation (termed “methylation mosa-
ics”). Using a detection technique comprising immunocyto-
chemical staining and counting of lymphocytes expressing
FMRP,7 Tassone et al8 identified a significant correlation between
FMRP expression and full scale IQ in males with full mutation/
premutation mosaicism and methylation mosaicism. These
authors observed that the presence of >50% FMRP expressing
lymphocytes correlated with non-retarded status (IQ>70).
These “high functioning” males, however, displayed some
learning disabilities and behavioural manifestations of fragile X
syndrome. The findings of improved function in these patients
show that the fragile X syndrome phenotype can be modified by
the production of substantial amounts of FMRP. The recognition
that substantial FMR1 expression ameliorates the phenotype
suggests that there may be a general threshold of FMRP
expression beyond which normal intellect results. Attempts to
define this possible expression threshold are complicated by
difficulties in precise quantification of intracellular FMRP,
possible differences in FMRP expression between blood and
other tissues, and background genetic and social effects on
intellect.
We report here on a subject who has a point mutation in the
CGG repeat region of FMR1 which reduces gene expression by
approximately 24% in a lymphoblastoid cell line established
from his peripheral blood. This young male has a history of
speech and developmental delay and low-normal IQ measures









Stanford-Binet Intelligence Scale (4th ed)
Verbal reasoning ND 83 89
Abstract/visual reasoning ND 89 79
Quantitative reasoning ND 108 93
Short term memory ND 58 67
Test composite ND 81 81
Vineland Adaptive Behavior Scale
Communication domain 69 101 94
Daily living skills domain 93 95 106
Socialisation domain 76 109 104
Motor skills domain 93 ND ND
Adaptive behaviour composite 77 102 101
ND=test or domain not done.
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(table 1). He was initially categorised as having fragile X syn-
drome based on his clinical presentation as a 2 year old with
delays in speech and also on the results of molecular diagno-
sis for FMR1, which mistakenly indicated a deletion within the
gene. Later investigations have shown that the proband does
not have a FMR1 deletion but a single base alteration within
the CGG repeat segment creating a new EagI restriction
enzyme site and hence leading to an unexpected change in
migration on Southern blot analysis (fig 1). To our knowledge,
this is the first report of a point mutation within the CGG
repeat of FMR1. This patient is instructive for two reasons.
One, he may represent a “natural experiment” whereby a sin-
gle base alteration within the CGG repeat sequence affects
FMRP production and results in mild phenotypic effects. Two,
the single base alteration creates a new restriction enzyme site
and illustrates the potential for misinterpretation of molecular
diagnostic tests for fragile X syndrome.
CASE REPORT
The proband was first evaluated for developmental and speech
delay in late 1993 at 30 months of age. He had a five word
vocabulary at this time and often used these words
inappropriately. A physical examination indicated height and
weight on the 10th centile, head circumference >95th centile,
prominent forehead, and speech delay. A follow up examina-
tion at 41⁄2 years showed height on the 45th centile, weight on
the 25th centile, head circumference >95th centile, long face,
prominent forehead, speech delay, but no hyperactivity.
Molecular genetic testing for FMR1 was ordered based on the
clinical findings.
Initially, the FMR1 alteration was identified as a deletion of
approximately 400 bp when a DNA fragment of ∼2.4 kb was
observed on Southern blot analysis (using probe StB12.3)
instead of the expected 2.8 kb fragment (fig 1A). Routinely,
Southern blot analysis using FMR1 specific DNA probes near
the CGG repeat and double restriction enzyme digestion with
EcoRI and EagI (or other methylation sensitive restriction
enzymes) generates a 2.8 kb fragment in males having
trinucleotide repeats within the normal range (<54
repeats).10 Polymerase chain reaction (PCR) analysis specific
for the FMR1 CGG repeat segment11 showed that the proband
had 31 repeats (his mother was homozygous for alleles with
31 repeats), suggesting the “deletion” did not involve the
FMR1 region containing the CGG repeat and the nearby flank-
ing sequence. Based on the Southern blot results and clinical
presentation of delays typical of fragile X syndrome in young
boys, the proband was expected to have fragile X syndrome.
Subjects with FMR1 deletions resulting in the loss of gene
expression invariably have fragile X syndrome indistinguish-
able from those who have the common trinucleotide repeat
expansion (full mutation).12 The PCR result was unusual since
it indicated no disruption of the region in FMR1 exon 1
containing the trinucleotide repeat, a known “hotspot” for
many deletion events.13 After several years of follow up evalu-
ation, however, it is clear that the proband has significantly
higher cognitive abilities than most males with fragile X syn-
drome (table 1).
The proband’s development has been frequently evaluated
since 1994, and he was enrolled in the Carolina Fragile X
Project, a long term study to follow the development of young
males with fragile X syndrome. Investigators in the Project
frequently noted that he was an outlier when compared to
other boys of a similar age with fragile X syndrome. More
recent cognitive-behavioural assessments at the ages of 6
years 10 months and 8 years 11 months found borderline to
low-normal cognitive skills and average adaptive behaviour
Figure 1 Southern blot and DNA sequence analysis of DNA from the proband. (A) Southern blot analysis. Lane 1 = patient; lane 2 =
patient’s mother; lanes 3, 5, and 6 = male controls (patients with normal alleles with <54 repeats); lane 4 = female control with both FMR1
alleles <54 repeats; lane 7 = full mutation control patient with complete methylation. (B) DNA sequence of FMR1 repeat region from the
patient. The trinucleotide repeat segment containing 31 repeats is underlined. The G to C transversion is noted by an asterisk and the newly
created EagI site is capitalised.
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levels for a child of his age. Unlike same aged males with frag-
ile X syndrome who show declines in IQ and adaptive behav-
iour levels,14 the proband’s test-retest IQ and adaptive behav-
iour scores were quite stable (table 1).
As a part of the Project’s evaluation, a blood sample was
obtained from the proband in 1998 to evaluate his production
of FMRP (performed at Kimball Genetics Inc). Fragile X DNA
testing was repeated along with FMRP testing, but Southern
blot analysis at this clinical testing laboratory showed a
normal result with a 2.8 kb fragment and no 2.4 kb fragment,
as seen in the previous testing. After consultation between the
laboratories involved in testing the proband, it was realised
that the respective Southern blot analysis protocols differed
slightly. While EagI was used as the methylation sensitive
restriction enzyme in the original study, another methylation
sensitive enzyme, NruI, was used in the second study. This
realisation led to DNA sequencing of the region around the
trinucleotide repeat segment. A single base transversion (G to
C) was identified embedded within the CGG repeat segment
(fig 1B). This alteration created a new EagI site 356 bp down-
stream from the EagI site normally detected, and led directly
to production of the 2.4 kb “deletion” fragment originally
detected in the proband. Thus, his “deletion” is, in fact, not a
deletion but a single base alteration. The 2.4 kb fragment has
been found (using EagI in the Southern blot procedure) in
both the proband’s mother (fig 1) and older sister (data not
Figure 2 FMR1 repeat segment and flanking DNA. (A) Diagram of a portion of the FMR1 gene showing commonly used restriction enzymes
for Southern blot analysis, fragment sizes, the StB12.3 probe, and the location of the repeat segment. The clustered methylation sensitive
restriction enzyme sites appear underlined in (B). (The second BssHII site contains overlapping restriction sites.) (B) DNA sequence of FMR1
promoter (GenBank Accession L29074) and repeat regions illustrating numerous potential single base alterations which may create new EagI
(E), BssHII (B), SacII (S), or NruI (N) restriction enzyme sites. Bases followed by * indicate potential new sites (* marks bases at any position
within the six base target recognition) and letters over the asterisks indicate which restriction enzyme site could be created by a single base
change. Within the CGG repeat segment, single base changes similar to that found in the proband can create only EagI or SacII sites (of the
four listed enzymes). However, these potential new sites can be created by point mutation at any consecutive CGGCGG (denoted as SE when
either a SacII or EagI site can be created by a single base change in the same position). The arrow indicates the location of the proband’s
mutation and the FMRP translation start site is denoted.
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